1-3 of 3
Masutaka Higashimura
Close
Sort by
Journal Articles

BCL6 Rearrangement Detected by FISH Analysis Is a Poor Prognostic Factor in the “Non-Germinal Center Phenotype” of Diffuse Large B-Cell Lymphoma.

Jun Takizawa, Sadao Aoki, Akihito Momoi, Toshiki Kitajima, Masutaka Higashimura, Naoya Nakamura, Yoshifusa Aizawa
Journal: Blood
Blood (2006) 108 (11): 4620.
https://doi.org/10.1182/blood.V108.11.4620.4620
Published: 2006
Journal Articles

A Phase II Clinical Study of Rituximab and High-Dose Biweekly THP-COP (Pirarubicin, Cyclophosphamide, Vincristine and Predonisolone) with G-CSF for Non-Hodgkin Lymphoma: Results of a Multicentric Study of NMLSG (Niigata Malignant Lymphoma Study Group).

Jun Takizawa, MD, PhD, Sadao Aoki, MD, PhD, Kazue Takai, MD, Tohri Kurasaki, MD, Keiichiro Honma, MD, Masutaka Higashimura, MD, Kouichi Nagai, MD, Akihito Momoi, MD, PhD, Koji Nikkuni, MD, PhD, Yoshufusa Aizawa, MD
Journal: Blood
Blood (2005) 106 (11): 4734.
https://doi.org/10.1182/blood.V106.11.4734.4734
Published: 2005
Journal Articles

High-Dose Bi-Weekly THP-COP Induction Treatment Followed by High-Dose Therapy with Autologous Peripheral Blood Stem Cell Transplantation for Advanced-Stage Follicular Lymphoma as First-Line Therapy.

Sadao Aoki, MD, PhD, Jun Takizawa, MD, PhD, Masutaka Higashimura, MD, Akihito Momoi, MD, Nobuhiro Tsukada, MD, PhD, Koji Nikkuni, MD, PhD, Nobuhiko Nomoto, MD, PhD, Yoshifusa Aizawa, MD
Journal: Blood
Blood (2004) 104 (11): 5207.
https://doi.org/10.1182/blood.V104.11.5207.5207
Published: 2004